ERBB2 and breast carcinoma: Collectively, analysis of the adaptive kinome response identified an immune response triggered by HER2-targeted therapy and confirmed the loss of key proliferative and breast cancer-associated kinases in the discrete, strongly molecular responsive subset of patients.